Myelodysplastic syndromes (MDS) are malignant disorders arising from hematopoietic stem cells, yet the precise epigenetic abnormalities occurring in the primitive stem cells remain poorly understood.

In conclusion, unraveling the involvement of DCs in MDS pathogenesis will provide a better understanding of the immune dysregulation mechanisms that are present in this disease. The phenotypical and ...

Somatically acquired genetic abnormalities lead to the salient features that define myelodysplastic syndromes (MDS): clonal hematopoiesis, aberrant differentiation, peripheral cytopenias, and risk of ...

A review of recent research into myelodysplastic syndromes (MDS) shows a range of potential therapeutic targets. New research into the pathogenesis of myelodysplastic syndromes (MDS) may help aid the ...

Determining the roles that various inflammatory markers and pathways play in lower-risk myelodysplastic syndromes (MDS) could lead to therapies that keep disease progression at bay. This team ...

Tobacco smoking is linked to specific genetic mutations in MDS, affecting chromatin modification and RNA splicing pathways. A dose-response relationship exists, with higher smoking intensity ...